Details
Stereochemistry | ACHIRAL |
Molecular Formula | C22H23N3O4 |
Molecular Weight | 393.4357 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COCCOC1=CC2=NC=NC(NC3=CC=CC(=C3)C#C)=C2C=C1OCCOC
InChI
InChIKey=AAKJLRGGTJKAMG-UHFFFAOYSA-N
InChI=1S/C22H23N3O4/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25)
Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders. The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors. | 2003 |
|
3D-QSAR and docking studies on 4-anilinoquinazoline and 4-anilinoquinoline epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. | 2003 Aug |
|
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer. | 2003 Dec |
|
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice. | 2003 Dec |
|
For investigational targeted drugs, combination trials pose challenges. | 2003 Dec 3 |
|
[Therapeutic implications of epidermal growth factor receptor in lung cancer]. | 2003 Nov |
|
[Inhibitors of epidermal growth factor receptor and colorectal cancer]. | 2003 Nov |
|
[Targeting of epidermal growth factor receptor and applications in ORL cancer]. | 2003 Nov |
|
Identifying predictive and surrogate markers of erlotinib antitumor activity other than rash. | 2003 Nov |
|
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? | 2003 Nov |
|
Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. | 2003 Nov |
|
Erlotinib: preclinical investigations. | 2003 Nov |
|
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer. | 2003 Nov |
|
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials. | 2003 Nov |
|
Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. | 2003 Nov |
|
Pharmacology of oral chemotherapy agents. | 2003 Nov-Dec |
|
Gateways to clinical trials. | 2003 Oct |
|
Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways. | 2003 Oct |
|
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma. | 2003 Sep |
|
Gateways to clinical trials. | 2003 Sep |
|
Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. | 2003 Sep-Oct |
|
Review of epidermal growth factor receptor biology. | 2004 |
|
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer. | 2004 |
|
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. | 2004 |
|
HER1/EGFR targeting: refining the strategy. | 2004 |
|
Gateways to clinical trials. | 2004 Apr |
|
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled? | 2004 Apr |
|
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer. | 2004 Apr |
|
Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2(+) cancer patients. | 2004 Apr 19 |
|
Novel treatments in non-small cell lung cancer. | 2004 Feb |
|
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. | 2004 Feb 9 |
|
Lung cancer: looking ahead in 2004. | 2004 Jan |
|
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. | 2004 Jan 1 |
|
Synthesis and SAR of potent EGFR/erbB2 dual inhibitors. | 2004 Jan 5 |
|
Gateways to clinical trials. | 2004 Jan-Feb |
|
Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors. | 2004 Jan-Feb |
|
Benzamides and benzamidines as specific inhibitors of epidermal growth factor receptor and v-Src protein tyrosine kinases. | 2004 Jul 1 |
|
Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. | 2004 Jun |
|
EGFR inhibitors square off at ASCO. | 2004 Jun |
|
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models. | 2004 Jun |
|
Epidermal growth factor receptor tyrosine kinase inhibitors. | 2004 Jun 14 |
|
The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. | 2004 Jun 15 |
|
The role of EGFR inhibitors in nonsmall cell lung cancer. | 2004 Mar |
|
[Bronchioloalveolar carcinoma (BAC)]. | 2004 Mar |
|
Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorage-independent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. | 2004 Mar |
|
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC. | 2004 Mar 1 |
|
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer. | 2004 May |
|
[Lung cancer: molecular targeting therapy]. | 2004 May |
|
New cytotoxic and molecular-targeted therapies of head and neck tumors. | 2004 May |
|
Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. | 2004 May 1 |
Sample Use Guides
The dose for NSCLC is 150 mg/day. The dose for pancreatic cancer is 100 mg/day. All doses of TARCEVA should be taken on an empty stomach at least one hour before or two hours after food
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2167
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
NDF-RT |
N0000175605
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
WHO-VATC |
QL01XE03
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
WHO-ATC |
L01XE03
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
LIVERTOX |
365
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
NDF-RT |
N0000175076
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
TARCEVA (AUTHORIZED: PANCREATIC NEOPLASMS)
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
||
|
EMA ASSESSMENT REPORTS |
TARCEVA (AUTHORISED: CARCINOMA, NON-SMALL-CELL LUNG)
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB00530
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
183321-74-6
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
CHEMBL553
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
4920
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
183321-74-6
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
C65530
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
8133
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
M5000
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | Merck Index | ||
|
183321-74-6
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
183321-74-6
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
C400278
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
ERLOTINIB
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
337525
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | RxNorm | ||
|
SUB16423MIG
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY | |||
|
176870
Created by
admin on Tue Oct 22 00:05:41 UTC 2019 , Edited by admin on Tue Oct 22 00:05:41 UTC 2019
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)